Janet Tse

Janet Tse focuses her practice on patent prosecution across a wide variety of technologies in biotechnology and life sciences, including nanotechnology, microfluidic devices, biomedical devices, diagnostics and treatment methods, precision medicine, personalized medicine, tissue engineering, biomaterials, drug delivery devices/systems, and assay platform technologies.

Recent Posts

Going (Way)back to the Future of Printed Publications

Posted by Janet Tse on Jun 2, 2017

Janet Tse

IPR challenges must rely on prior art “patents or printed publications” as the basis for invalidating US patents. But what if a useful prior art reference is not a typical printed publication such as a scientific literature reference or industry journal report? We explored the subject of what constitutes a prior art printed publication in a recent post; now we’ll take a closer look at this issue as it relates to digital content. Two related IPR decisions, Coalition for Affordable Drugs VIII, LLC v. The Trustees of the University of Pennsylvania (IPR2015-01835, Paper 56 and IPR2015-01836, Paper 58), demonstrate that it can sometimes be challenging to prove that a reference qualifies as a printed publication … leaving the petitioner wishing they could hop in the DeLorean to go back and change the prior art.

Read More

Topics: Kyle Bass, BioPharma, Printed Publications

Wolf Greenfield's Post-Grant Blog

Here, the Post-Grant Proceedings Group
at Wolf Greenfield keeps you up to date
on the latest decisions and best practices, and what they mean for you. Learn more about the group and its members.

New Call-to-action
New Call-to-action
New Call-to-action

Subscribe to Email Updates

Recent Posts

Follow Us

This blog is intended to promote thought and debate on developing areas of the law. The opinions, commentary and characterizations of cases provided on this blog are not legal advice and do not represent the opinions of Wolf Greenfield or its clients.